Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multi-centre non-interventional study of patients who are treated with any HMGCoA reductase inhibitor available in Croatia (rosuvastatin, simvastatin, atorvastatin and fluvastatin) for at least 6 months. All HMG-CoA reductase inhibitors must be prescribed in accordance with SmPCs approved in Croatia. Data collection for each patient will take place at a single visit. The investigator will complete a Case Report Form with the patient's demographics, the presence of the factors for high cardiovascular risk, current treatment, cholesterol values as well as with further treatment decision.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Patients with hypercholesterolaemia |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | |
| Percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | |
| Number of patients with high cardiovascular risk reaching the LDL-C goals according to the Fourth Joint European Task Force guideline. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients treated by specialist
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Svjetlana Serdar | AstraZeneca | Study Chair |
| Karin Otter | AstraZeneca | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Biograd na Moru | Croatia | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
| During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Number of patients with high cardiovascular risk reaching the total cholesterol goals according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Percentage of patients with high cardiovascular risk reaching the LDL-C goals according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Percentage of patients with high cardiovascular risk reaching the total cholesterol goals according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Bjelovar |
| Croatia |
| Research Site | Crikvenica | Croatia |
| Research Site | Čakovec | Croatia |
| Research Site | Dubrovnik | Croatia |
| Research Site | Gospić | Croatia |
| Research Site | Karlovac | Croatia |
| Research Site | Koprivnica | Croatia |
| Research Site | Krapina | Croatia |
| Research Site | Krapinske Toplice | Croatia |
| Research Site | Opatija | Croatia |
| Research Site | Osijek | Croatia |
| Research Site | Poreč | Croatia |
| Research Site | Pula | Croatia |
| Research Site | Rijeka | Croatia |
| Research Site | Sisak | Croatia |
| Research Site | Slavonski Brod | Croatia |
| Research Site | Split | Croatia |
| Research Site | Stubičke Toplice | Croatia |
| Research Site | Umag | Croatia |
| Research Site | Vinkovci | Croatia |
| Research Site | Virovitica | Croatia |
| Research Site | Virovitica- Slatina | Croatia |
| Research Site | Vukovar | Croatia |
| Research Site | Zadar | Croatia |
| Research Site | Zageb | Croatia |
| Research Site | Zagreb | Croatia |
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided